当前位置： SCI文献检索 > NATURE期刊下所有文献 > Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia.

Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia.

Abstract：

:Recurrent chromosomal translocations involving the mixed lineage leukaemia (MLL) gene initiate aggressive forms of leukaemia, which are often refractory to conventional therapies. Many MLL-fusion partners are members of the super elongation complex (SEC), a critical regulator of transcriptional elongation, suggesting that aberrant control of this process has an important role in leukaemia induction. Here we use a global proteomic strategy to demonstrate that MLL fusions, as part of SEC and the polymerase-associated factor complex (PAFc), are associated with the BET family of acetyl-lysine recognizing, chromatin 'adaptor' proteins. These data provided the basis for therapeutic intervention in MLL-fusion leukaemia, via the displacement of the BET family of proteins from chromatin. We show that a novel small molecule inhibitor of the BET family, GSK1210151A (I-BET151), has profound efficacy against human and murine MLL-fusion leukaemic cell lines, through the induction of early cell cycle arrest and apoptosis. I-BET151 treatment in two human leukaemia cell lines with different MLL fusions alters the expression of a common set of genes whose function may account for these phenotypic changes. The mode of action of I-BET151 is, at least in part, due to the inhibition of transcription at key genes (BCL2, C-MYC and CDK6) through the displacement of BRD3/4, PAFc and SEC components from chromatin. In vivo studies indicate that I-BET151 has significant therapeutic value, providing survival benefit in two distinct mouse models of murine MLL-AF9 and human MLL-AF4 leukaemia. Finally, the efficacy of I-BET151 against human leukaemia stem cells is demonstrated, providing further evidence of its potent therapeutic potential. These findings establish the displacement of BET proteins from chromatin as a promising epigenetic therapy for these aggressive leukaemias.

journal_name

Nature

journal_title

Nature

authors

Dawson MA,Prinjha RK,Dittmann A,Giotopoulos G,Bantscheff M,Chan WI,Robson SC,Chung CW,Hopf C,Savitski MM,Huthmacher C,Gudgin E,Lugo D,Beinke S,Chapman TD,Roberts EJ,Soden PE,Auger KR,Mirguet O,Doehner K,Delwel R,

doi

10.1038/nature10509

subject

Has Abstract

pub_date

2011-10-02 00:00:00

pages

529-33

issue

7370

eissn

0028-0836

issn

1476-4687

pii

nature10509

journal_volume

478

pub_type

杂志文章

在线工具

Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia.